MET and non-small cell lung carcinoma: The novel ATP-competitive and blood–brain-barrier-permeable inhibitor capmatinib is approved by the FDA for the treatment of NSCLC patients with hyperactivation of the MET pathway caused by an exon14 skipping mutation in the MET gene [69].